Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Webinar | Viewing the Orange Book Under a Microscope: The Regulatory Framework & its Implications for Branded Drug Makers

Thursday, April 14th, 2022, 1:30 pm EDT

Webinar | Viewing the Orange Book Under a Microscope: The Regulatory Framework & its Implications for Branded Drug Makers

This webinar took place on: Thursday, April 14th, 2022, 1:30 pm EDT

This webinar has ended.

Congress passed the Hatch-Waxman Act to establish a framework that encourages innovation by branded drug makers, but shortens the time to market for generic drug makers. A critical aspect of that framework is the Food and Drug Administration (FDA)’s Orange Book. The Orange Book provides a listing of approved drug products and their related patent and regulatory exclusivities, which is at the center of all Hatch-Waxman litigation disputes.

On Thursday, April 14, please join Fish attorneys Kelly Del Dotto and Megan Chacon for “Viewing the Orange Book Under a Microscope: The Regulatory Framework & its Implications for Branded Drug Makers.” Our speakers will discuss in detail the importance of the Orange Book in Hatch-Waxman litigation, as well as its purpose and value within the legal industry.

  • How the Orange Book Fits into the Hatch-Waxman Framework
  • Orange Book Listable Patents and Litigation Strategy
  • Summary of the Changes in the January 2021 “Orange Book Act”
  • What’s Next: FDA’s Review of What Patents can be Listed in the Orange Book

Download a Copy of the Webinar Slides

Related Services
Related Industries